NCT04468607View on ClinicalTrials.gov

A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

October 16, 2024

Study Completion Date

October 16, 2024

Conditions
Colorectal Cancer
Interventions
DRUG

BLYG8824A

BLYG8824A will be administered at a flat dose independent of body weight.

Trial Locations (6)

3000

Peter MacCallum Cancer Centre, Melbourne

28040

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid

31008

Clinica Universitaria de Navarra, Pamplona

37203

SCRI Oncology Partners, Nashville

91010

City of Hope, Duarte

08035

Hospital Universitario Vall d'Hebron - PPDS, Barcelona

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT04468607 - A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter